The accuracy, reliability, and clinical utility of DPNCheck has been established across more than three decades of independent research published in leading medical journals.
DPNCheck measures sural nerve conduction velocity and sensory nerve action potential amplitude at the point of care. These are widely accepted biomarkers of peripheral nerve function. The device's validity and reliability against conventional electromyography-lab nerve conduction studies has been confirmed across multiple independent research groups, patient populations, and clinical settings.
Normal reference limits are clearly defined: amplitude above 4 microvolts and conduction velocity above 40 m/s. Results outside these thresholds indicate peripheral neuropathy and can be used to stage severity.
Summary sensitivity for diabetic peripheral neuropathy detection, determined by bivariate meta-analysis across multiple independent validation studies.
*Specificity vs. healthy controls is 95%. Sensitivity and specificity figures are against traditional nerve conduction study as reference standard.
Independent peer-reviewed research using DPNCheck published across endocrinology, neurology, diabetes care, and primary care journals from 2006 to present.